ReviewCurrent oncology reports2017
Update on Management of Cancer-Related Cachexia.
Review in Current oncology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05731076 (Efficacy of Self-Management Support on Nutritional Status in Lung Cancer Patients With Cancer Cachexia Syndrome), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Self-Management Support on Nutritional Status in Lung Cancer Patients With Cancer Cachexia Syndrome: A Randomized Clinical Trail
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Cachexia Index in Patients with Gastrointestinal Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2024Pooled it
- Ghrelin for the management of cachexia associated with cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Phospholipid Glutathione Peroxidase Overexpression Mitigates Cancer Cachexia by Protecting Muscle Mass and Lowering Inflammation.Journal of cachexia, sarcopenia and muscle · 2026Article
- NF-κB Signaling as a Central Driver of Cancer Cachexia.Cancers · 2026Review
- Distinct Metabolomic Alterations Are Associated With Physical Function, Weight Loss, and Muscle Mass in Men With Cancer.Journal of cachexia, sarcopenia and muscle · 2026Article
- Cancer Cachexia.Advances in experimental medicine and biology · 2025Review
- Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer.BMC cancer · 2024Article
- Association of a newly developed Cancer Cachexia Score with survival in Stage I-III colorectal cancer.Langenbeck's archives of surgery · 2023Article
- Wheel running improves fasting-induced AMPK signaling in skeletal muscle from tumor-bearing mice.Physiological reports · 2021Article
- Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.Oncoimmunology · 2021Article
- Activation of the Adipose Tissue NLRP3 Inflammasome Pathway in Cancer Cachexia.Frontiers in immunology · 2021Article
- The Electronic Frailty Index is Associated with Increased Infection and All-Cause Mortality Among Older Patients with Primary Lung Cancer: A Cohort Study.Clinical interventions in aging · 2021Article
- Cachexia Disrupts Diurnal Regulation of Activity, Feeding, and Muscle Mechanistic Target of Rapamycin Complex 1 in Mice.Medicine and science in sports and exercise · 2020Article
- Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I.Acta pharmacologica Sinica · 2020Article
- Understanding sex differences in the regulation of cancer-induced muscle wasting.Current opinion in supportive and palliative care · 2018Review
- Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin.JCI insight · 2018Article
- What is next after anamorelin?Current opinion in supportive and palliative care · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cachexia is a metabolic syndrome driven by inflammation and characterized by loss of muscle with or without loss of fat mass. In cancer cachexia, the tumor burden and host response induce increased inflammation, decreased anabolic tone, and suppressed appetite leading to the clinical presentation of reduced body weight and quality of life (QOL). There is no approved treatment for cancer cachexia, and commonly used nutritional and anti-inflammatory strategies alone have proven ineffective for management of symptoms. Several other pharmacological agents are currently in development and have shown promise as a clinical strategy in early-phase trials. Recently, it has been proposed that multimodal strategies, with an anabolic focus, initiated early in the disease/treatment progression may provide the most therapeutic potential for symptom management. Here we review the data from recent clinical trials in cancer cachexia including pharmacological, exercise, and nutritional interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.